Clinical trial
A Pharmacogenomic Study of Candesartan in Heart Failure
NCT00400582 · Montreal Heart Institute, Other · Completed
Key facts
| NCT number | NCT00400582 |
|---|---|
| Title | A Pharmacogenomic Study of Candesartan in Heart Failure |
| Official title | Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms |
| Lead sponsor | Montreal Heart Institute, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | Candesartan up to 32 mg daily |
| Enrollment | 300 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Nov 17, 2006 |
| Last update posted | Jul 22, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: